- Home
- Publications
- Publication Search
- Publication Details
Title
Personalized Targeted Therapy for Lung Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 13, Issue 9, Pages 11471-11496
Publisher
MDPI AG
Online
2012-09-14
DOI
10.3390/ijms130911471
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).
- (2017) M. J. Boyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.
- (2017) L. Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC).
- (2017) C. Sorlini et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction erlotinib or gemcitabine/carboplatin factorial assignment therapy in stage IIIA-N2 non-small cell lung cancer.
- (2017) W. Zhong et al. JOURNAL OF CLINICAL ONCOLOGY
- Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
- (2017) A. Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
- (2017) Marina Chiara Garassino et al. JOURNAL OF CLINICAL ONCOLOGY
- LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Treatment of Lung Cancer With Targeted Therapy
- (2012) Philip T. Cagle et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
- (2012) Gargi Ghosh et al. BMC CANCER
- A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
- (2012) Takashi Kobayashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance
- (2012) Takenori Ogawa et al. CELL CYCLE
- High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma
- (2012) Y. Lee et al. CLINICAL CANCER RESEARCH
- Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
- (2012) Fausto Petrelli et al. Clinical Lung Cancer
- Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
- (2012) A. Ballestrero et al. CURRENT CANCER DRUG TARGETS
- ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
- (2012) Giorgio Scagliotti et al. EUROPEAN JOURNAL OF CANCER
- Lung cancer in never smokers – A review
- (2012) Sébastien Couraud et al. EUROPEAN JOURNAL OF CANCER
- Emerging personalized oncology: sequencing and systems strategies
- (2012) William Cho et al. Future Oncology
- Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non–Small-Cell Lung Cancer
- (2012) Su-Jung Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Genomics: Technology, Discovery, and Translation
- (2012) Ben Tran et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
- (2012) Michele Milella et al. Journal of Thoracic Oncology
- Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer
- (2012) M. Catherine Pietanza et al. Journal of Thoracic Oncology
- The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis
- (2012) Simon Ekman et al. Journal of Thoracic Oncology
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- (2012) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
- (2012) Giulio Metro et al. LUNG CANCER
- Molecular pathology of lung cancer: key to personalized medicine
- (2012) Liang Cheng et al. MODERN PATHOLOGY
- Abstract C191: Preclinical investigation of the antitumor efficacy in lung cancer of Y15, a novel focal adhesion kinase inhibitor.
- (2012) G. K. Dy et al. MOLECULAR CANCER THERAPEUTICS
- The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
- (2012) Y. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of small molecule cancer drugs: Successes, challenges and opportunities
- (2012) Swen Hoelder et al. Molecular Oncology
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
- (2011) C.P. Belani et al. CANCER TREATMENT REVIEWS
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
- (2011) Y. S. Ju et al. GENOME RESEARCH
- A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma
- (2011) Ornella Belvedere et al. GENOMICS
- Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
- (2011) S. Matsuura et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Personalized medicine in lung cancer: what we need to know
- (2011) Tony S. K. Mok Nature Reviews Clinical Oncology
- Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
- (2011) Giulia M. Stella et al. RESPIRATORY MEDICINE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
- (2010) Lynette M. Sholl et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
- (2010) Christian C. Lee et al. BIOCHEMICAL JOURNAL
- Epidermal Growth Factor Receptor Biomarkers in Non–Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma
- (2010) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
- (2010) Yihua Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705
- (2010) Hiroshige Yoshioka et al. Journal of Thoracic Oncology
- A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations
- (2010) Dong-Wan Kim et al. LUNG CANCER
- Head and Neck Squamous Cell Carcinoma: New Translational Therapies
- (2010) Anthony Prince et al. MOUNT SINAI JOURNAL OF MEDICINE
- The mutation spectrum revealed by paired genome sequences from a lung cancer patient
- (2010) William Lee et al. NATURE
- Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
- (2010) Filip Janku et al. Nature Reviews Clinical Oncology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
- (2009) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
- (2009) Rafael Rosell et al. PLoS One
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
- (2008) K Tamura et al. BRITISH JOURNAL OF CANCER
- Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops
- (2008) A. F. Gazdar et al. Cancer Prevention Research
- Advances in Breast Cancer: Pathways to Personalized Medicine
- (2008) O. I. Olopade et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction
- (2008) Andrew H. Ko et al. GASTROENTEROLOGY
- Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
- (2008) Kenji Sugio et al. LUNG CANCER
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story
- (2007) Lecia V. Sequist et al. Annual Review of Medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started